NR1H3 and fatty liver disease: A recent study revealed that 3 significantly regulated target genes associated with RCT via stimulating the transactivation of LXRα/β, further confirmed as a potent pharmaceutical agent for the treatment of atherosclerosis and hypercholesterolemia, and the prevention of the potential side effect of hepatic steatosis as well (Hien et al., 2017).